Price Alert

Genetic Technologies Limi... (GENE)

NASDAQ: GENE · Real-Time Price · USD

0.77

0.01 (0.65%)

At close: Nov 14, 2024, 10:00 PM

0.65% (1D)

Bid	n/a
Market Cap	111.24M
Revenue (ttm)	8.76M
Net Income (ttm)	-12.02M
EPS (ttm)	-0.02
PE Ratio (ttm)	-38.25
Forward PE	n/a
Analyst	n/a

Ask	n/a
Volume	0
Avg. Volume (20D)	0
Open	undefined
Previous Close	0.77
Day's Range	0.77 - 0.77
52-Week Range	0.67 - 3.59
Beta	0.48

About GENE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GENE

Website n/a

Full Company Profile

News

1 month ago · benzinga.com

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Ionis Pharmaceuticals Inc. IONS reported second-quarter adjusted earnings of 85 cents on Wednesday. The company reported an adjusted loss of $35 million a year ago.

2 months ago · seekingalpha.com

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects

I maintain my Buy rating on Rhythm Pharmaceuticals due to its leadership in rare genetic obesity treatments. The company's innovative therapies address significant unmet needs, supporting long-term gr...

2 months ago · accessnewswire.com

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Phar...

3 months ago · businesswire.com

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the...